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the aIds epidemic: social, 
scientific and economical 
impacts and perspectives
Dirceu B. Greco
“there have been as many plagues as wars in history;
 yet always plagues and wars take people equally by surprise.”
(albert Camus, The Plague)
Introduction
In the last few years, several new diseases have been discovered, some of them very serious and difficult to control. since the discovery of the Human Immunodeficiency virus (HIv), in the beginning of the 1980’s, 
more than twenty pathogens have been described and found to be involved in 
several diseases these new diseases add to existing ones – whose incidence has 
been increasing – and, among the new microbial agents, there are several viruses 
against which the currently available therapeutic arsenal is insufficient.
the current situation has peculiar features, among which are:
a) Increased size of the world population (more than six billion people);
b) Large population movements, both spontaneous (leisure or business 
travels) and induced (wars, droughts and other environmental disasters);
c) Higher number of people suffering from diseases due to higher exposure 
of specific groups to risk situations -  such as prisoners , residents in senior citizen 
homes and orphanages, schools students, migrants, homeless populations and 
citizens living in precarious conditions;
d) Intense and rapid environmental changes, related to economical and 
industrial development;
e) Lower social support, higher unemployment, disorganized urbanization;
f) Intense use of anti-microbial drugs, favoring, on the one hand, the 
emergence of resistant strains and, paradoxically, contributing on the other hand 
to the development of resistance caused by lack of compliance with treatments.
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It is a well-known fact that infectious and parasitic disease agents are 
part of our habitat (our ecology), surely making it unlikely (and many times 
undesirable) that they ever be completely eliminated. the complex ecological 
relationships (host-environment-parasites) are yet to be entirely understood, and 
the importance of maintaining this balance for the balance of life itself should be 
underscored. on the other hand, the technical knowledge accumulated in the last 
few decades has already indisputably demonstrated the close relationship between 
improvement of basic sanitary conditions and lower incidence of infectious and 
parasitic diseases. those conditions include, but are not limited to availability of 
safe water supplies, adequate sanitary sewage systems, healthy diets, education and 
employment.
The hegemony of the market culture
the dismantling of the former soviet union and the current hegemony 
of the central capitalist single current of thought in peripheral countries has 
brought serious problems to their populations. the drive for efficiency at any cost, 
concentration of wealth, weakening of social public policies have contributed to 
discard the notion of nation in favor of a large global market, where actions and 
policies are decided by the central countries.
The Aids epidemic
as Camus has suggested, aids took the world by surprise, as did other 
plagues. this happened even as industrialized societies boasted at the end of the 
20th century that they were able to control all infectious diseases by means of 
immunization or treatment.
the emergence, in the end of the 1980’s, of this serious and mortal 
epidemic, involving several aspects of human relations (sex, death, prejudice), 
may serve as an example for the fight against other diseases. the immodest 
expectation to be able to control infectious diseases by the end of the 20th was 
crushed, in the specific example  of the aids epidemic, by the difficulty to put 
into effect  proven preventive strategies (change of behavior, use of condoms, safe 
blood banks, use of disposable syringes), to develop truly effective and affordable 
drugs and to develop efficient vaccines and make them available.
Contradictorily and positively, there were beneficial by-products brought 
by the  response to the global dissemination of this serious epidemic. such as the 
involvement of civil society clamoring for access to information, for more funds 
for research and new drugs, as well as the opportunity to expand the discussion 
on complex themes (such as sexuality, death, use of illicit drugs, confidentiality). 
additionally,   the participation of persons living with HIv/aids  in medical 
conferences and governmental disease control committees has contributed to 
change the paradigm of vertical programs, in which decisions were usually taken 
top-to-bottom, with no broader discussions or correct assessment of possible risks 
and benefits.
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Brazil has been facing the epidemic in an unusually courageous way – 
comparatively to other programs of disease control -, by distributing (and locally 
producing) condoms and anti-retroviral drugs at no additional cost to patients, 
as well as implementing a public network of laboratories for diagnosis, patient 
follow-up and research support. these measures, even if not sufficient to interrupt 
the dissemination of the epidemic, have increased survival rates and improved the 
quality of life of people living with aids, as well as improved the techno-scientific 
conditions of healthcare professionals.
Scientific, economical, social and ethical impact
Science and ethics
as far as science is concerned, the amount of knowledge related to 
HIv/aIds has been truly remarkable since the first clinical cases were 
reported in 1981 (okie, 2006), and, even before the discovery of its etiological 
agent, it was found to be infectious and sexually transmissible. the discovery 
of HIv took little more than two years, and its causal relationship to aids 
was established in 1984. In 1985, there were tests available for serologic 
diagnostics. not long after that, these tests began to be used in triages of 
blood to be transfused and, in 1987, the beneficial, albeit ephemeral, effect of 
zidovudine against HIv was demonstrated. about ten years later (1996), the 
efficacy of the association of anti-retroviral agents was proven, inaugurating 
a new era for the control of the epidemic and providing relief to millions 
of people infected with HIv. However, this scientific victory, as it had also 
been the case in similar situations, has not reverted into global benefits, 
being instead restricted mainly to the central, industrialized countries, and 
highlighting the pressing need to discuss the ethics of access to scientific 
progress by all the people who need it. 
In terms of ethics, aids has unveiled a myriad of legal and, particularly, 
ethical challenges – several of which date from before this epidemic – both in 
industrialized countries (Beecher, 1996; Rothman & Michels, 1994) and in 
developing nations (Bayer & Gostin, 1989; Connor, 1989). these challenges 
belong to well-known categories:
 • allocation of scarce resources;
 • Prevention;
 • secret and confidentiality;
 • discrimination;
 • Public health protection vs. individual protection (public health vs. 
individual needs);
 • Research involving human beings;
 • application of the principles of distributive justice.
on the topic of research, for many years internationally collaborative 
research projects have occurred almost always with financing agencies, 
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researchers, institutions and, many times, the projects themselves coming from 
developed countries and the participation , usually small, from researchers and 
institutions from developing countries.
the aids pandemic increased the need for effective international 
collaboration, and the role of the World Health organization (WHo), initially 
by means of the Global Program on aids and its successor, unaIds, has been 
undoubtedly important in this process. More recently, other philanthropic, 
independent or non-governmental organizations, such as the Global Fund for 
Malaria, tuberculosis and aids (whose aim is to increase the availability of anti-
retroviral drugs through new funds)(www.unitaid.eu) and foundations (Bill and 
Melinda Gates, Bill Clinton, among others) have been created. If the latter, on 
the one hand, expands the amount of available resources, on the other hand, it 
risks lowering state resources and decreasing the pressure for the state to fulfill 
its mandated role in public health care. another risk is that the agenda gets to 
be defined solely by the financing entities (with all the associated political and 
financial consequences).
Collaboration in aIds research has made it necessary to re-examine legal 
and, especially, ethical aspects of research in general. the practical difficulties 
faced by collaborative efforts are not exclusive to aIds research, but the 
particular characteristics of this epidemic have made many points more visible and 
sensitive. the issues specific to the epidemic and the problems that are expected 
to be solved will be useful in the fight against other endemic or epidemic diseases. 
Many publications, seminars and debates have been held to discuss these topics 
and it is worth emphasizing some points: 
It is crucial to develop universally acceptable ethical principles, which 
should consider culturally relevant approaches for the implementation of 
research projects. the declaration of Helsinki (2000) can and should serve 
as one of their main ethical references.
all researchers, both from developed and developing countries, should 
collaborate during all stages of the study, from the development of the 
protocol to the publication and application of the results.
decisions about access to the products which result from the studies 
should be made based upon the principles of justice, meaning that 
those who have to cope with the heaviest burden should receive the 
appropriate benefits. volunteers should have access to drugs, vaccines, 
interventions, prevention strategies and any other benefits resulting 
from the study.
Financing of studies should include funds for strengthening local 
capacities, not only those related to the specific aims of the project, but 
also local infra-structure, institutions and host country capacity to conduct 
research projects.
It is extremely important to deepen the discussion on the informed 
consent process.  such consent should be obtained in ways that respect the 
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dignity and cultural values of  the volunteers.
the confidentiality of the data should be protected during the whole 
project. the inclusion of vulnerable individuals shall warrant special 
justification and appropriate protection and should occur only when 
the aim of the project is to benefit those persons. Individuals may be 
considered vulnerable when: (a) they are incompetent to give valid consent; 
(b) they are potentially vulnerable to induction, coercion or exploitation. 
these groups include, but are not limited to: children, people with mental 
illnesses or disorders, and prisoners.
despite the existence of several international and national ethical rules, 
the urgent need to find mechanisms to control the exponential dissemination 
of the aids epidemic, the raise in deaths by tuberculosis and the increase in 
the incidence of other diseases, old and new (such as malaria, dengue fever and 
cholera), have been used as an argument (Greco, 2000) to lower the ethical 
standards required to carry out studies involving human beings, especially in 
developing countries. With the justification that poor countries do not have access 
to the ideal treatments anyway, there seems to have emerged a concerted action to 
modify several items of the declaration of Helsinki – a declaration which has been 
considered by the Canadian Medical association as the “stone tablet of medical 
research ethics” – especially those related to access to healthcare and to the use of 
placebo as an experiment control.
Double-standard in clinical research
the migration of randomized trials to developing countries brought 
with it the risk of lowering ethical requirements. there is no intention here of 
demonizing the pharmaceutical industry - which has an important role in the 
development of many  products - by attributing all non-ethical trials to them, 
since such trials have also been carried out by national and international agencies, 
with the collaboration of local and/or international researchers.
one of the triggers of the debate on international research ethics has 
been the aIds epidemic, whose causing virus, differently from other infectious 
diseases, does not respect national boundaries. In this epidemic, not only the 
need for better epidemiological knowledge but also the perceived urgency to 
develop and test the efficacy of anti-retroviral drugs led to an exponential increase 
in the number of international multi-centric clinical trials. In this context, 
developing countries appear as the ideal scenario: same virus, same disease, 
high prevalence and incidence of the infection, as well as often less demanding 
volunteers, authorities and researchers.
It is difficult, if not impossible, to pinpoint the origin of the heated 
discussions on ethical requirements for clinical studies, but it is worth 
mentioning at least one trigger of this ethical battle. In 1997, an incisive 
editorial written by dr. Marcia angell (1997) – then editor of the New england 
Journal of Medicine – criticized the ethics of studies financed by the united 
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states’ national Institutes of Health (nIH) on the prevention of maternal-fetal 
transmission of HIv which had been carried out in african countries, in the 
dominican Republic and in thailand. these studies were conducted at a time 
when the results of the aCtG 076 studies (Connor et al., 1994; CdC, 1994) 
had already shown that the risk of HIv transmission decreased substantially 
when zidovudine was orally administrated during pregnancy, intravenously 
during birth and orally to the newborn. In the trials criticized by dr. angell, 
zidovudine (aZt) was administered for a shorter period during pregnancy 
and the intravenous dose was eliminated, in comparison with a control group 
that received only placebo. according to her, the use of placebo in this study 
reminded the unethical tuskegee syphilis study (1932-1972) (Fairchild & Bayer, 
1999). this editorial and other related articles provoked intense discussions and 
was possibly one of the reasons for subsequent pressure from north-american 
regulating agencies and researchers (Levine, 1999) to modify the ethical 
requirements defined in the declaration of Helsinki (1996). their intention was 
to change the items related to the obligation to provide access to the best health 
treatments to all volunteers (item 30) in clinical trials carried out in any part 
of the world, as well as those related to the use of placebo when there exists an 
efficient treatment.
using fallacious arguments, a proposal from the american Medical 
association was sent to the World Medical association in which those items 
were grossly altered, allowing for the use of placebo when there was no efficient 
treatment available in the country where the trial was being conducted and 
substituting best locally available medical care for the best medical care. this 
change would justify, for example, the methodological design of the trials 
criticized above.
this proposal was rejected, and the 52nd General assembly of the World 
Medical association (edinburgh, 2000) maintained the restrictions on the use of 
placebo (item 29) and added the requirement to provide post-study access to the 
best medical care demonstrated in the study (item 30). However, pressures both 
from regulating agencies and the pharmaceutical industry were very intense, and 
the WMa added (2002-2004) two clarifying notes to these items. these notes 
made it possible to avoid the requirement to treat all volunteers with equal respect 
and warrants, independently from their origin or economical power, establishing 
the possibility of an ethical double standard in clinical research.
In the same occasion (2004), the Food and drug administration (Fda), 
responsible for approving and registering drugs in the united states, proposed 
that clinical research projects carried out in other countries and not conducted 
under an application for a Investigational new drug (Ind) need not fulfill the 
requirements of the declaration of Helsinki any longer. this decision affects 
the rules for medication research carried out outside of the united states which 
has not applied for an Fda Ind registration. the Fda rules used to require 
that studies submitted for a new experimental medication (nda) be carried 
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out according to the rules that protected the volunteers the most, be them the 
declaration of Helsinki or the local legislation. this new proposal requires 
only that the study be conducted according to the International Conference on 
Harmonization (ICH) Guideline for Good Clinical Practice. these guidelines 
deal mainly with procedures and  not with ethical issues. For example, the 
guidelines do not mention the issue of conflict of interests, the need to publish 
the results or post-study volunteer access  to the treatments that have proved 
effective, as determined by the declaration of Helsinki. the Fda claimed to 
be concerned with “ensuring the quality of data”, thus the need for the ICH 
Guideline. It would be more logical then to require studies to comply both with 
the ICH Guideline and the declaration of Helsinki. It also stated that there 
was concern about the possibility of the declaration of Helsinki being modified 
“independently from the authority of the Fda”. Ironically, the Fda did not 
consider the current version of this declaration (edinburgh, 2000), referring to 
the 1989 version, which had been automatically cancelled with the approval of the 
2000 version.
the Fda and other north-american agencies, as well as the department 
of Health and Human services and the us pharmaceutical industry, have 
opposed many improvements in several international ethical documents. their 
efforts have not been entirely successful in the case of the declaration of Helsinki, 
which may explain this new proposal. since 1996, in many reports and discussion 
meetings on the declaration of Helsinki and the 2002 version of the Council for 
International organizations of Medical sciences (CIoMs)’ international ethical 
Guidelines for Biomedical research involving Human Subjects (Phanuphak, 1998), 
there was pressure  to limit the rights of clinical trials volunteers, particularly in 
developing countries. 
the Fda concerns are related to two areas, which are conveniently absent 
from the CIoMs Guidelines. In relation to the use of placebo, the us agency 
complained that the 2000 declaration prevented the use of placebo for simple, 
less serious diseases. the Fda participated in the movement to introduce in 
the declaration (article 29) a clarifying note that makes it easier to use placebo. 
and it also supports its use in developing countries, in clinical studies on serious 
diseases even when there is efficient treatment, something which is not authorized 
by the declaration of Helsinki.
Fda and other agencies within its parent agency, the department of 
Health and Human services (dHHs), and the u.s. pharmaceutical industry have 
led the charge against many of the substantive improvements in these updates, 
particularly in the doH.  But it is with the doH that their efforts have met with 
the least success.  this suggests an alternative motivation for the Fda’s proposal.  
In a series of published articles in medical journals,,, as well as in a number of 
meetings on the doH and a related document, the Council for International 
organizations of Medical sciences (CIoMs) International ethical Guidelines 
for Biomedical Research Involving Human subjects, dHHs and its agencies 
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The global symbol of the fight against Aids was displayed at the conference in Durban  
(South Africa).
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have spearheaded efforts to limit the rights of clinical trial subjects and their 
communities, particularly in developing countries. 
Furthermore, the Council and the Fda argue against the requirement 
that medication that proves to be efficient be given to all participants at the end 
of the study (Helsinki declaration, article 30). this requirement is particularly 
critical in developing countries, where those who receive the study’s medication 
may have their treatment abruptly interrupted and those in the control group may 
have their access denied to treatments whose efficacy they helped prove.
despite several criticisms made directly on the Fda’s page and in scientific 
literature, this substitution decision was officially taken by the agency in 2008.
New proposals to change the Declaration of Helsinki
In May 2007, the World Medical association (WMa) created a new 
working group, with members from Brazil, Germany, Japan, south africa 
and sweden, to review the declaration of Helsinki with the following aims: 
“(a) identifying gaps in content, but avoiding a complete reopening of the 
document for modification; (b) using the review process to promote the Helsinki 
declaration”. according to the WMa’s ethical Committee coordinator, dr. eva 
Bagenholm,
although many of the proposed changes are small, there are significant changes 
being proposed, particularly to enhance protection and benefits to volunteers in 
research projects and new items related to data registry and consent for research 
using human tissue.
the most controversial points of this new proposal were exactly the ones 
related to the use of placebo and post-study access to medications proven to be 
effective – WMa’s proposal (table 1) suppresses the clarifying notes, but keeps 
their content within the specific items, that is, it maintains the risk of placebo use 
even when there is efficient treatment and reduces the obligation to provide post-
study access to medication. the latter is rather weakened by the proposal  that 
“the protocol should describe arrangements for post-study access by study subjects 
to interventions identified as beneficial in the study or access to other appropriate 
care or benefits”, which may be interpreted as it being enough to describe in 
the project what shall be offered (which may be nothing) for it to be ethically 
acceptable.
In august 2008, the Brazilian Medical association (Associação Médica 
Brasileira, aMB) organized a seminar in são Paulo, together with the Federal 
Council of Medicine (conselho Federal de Medicina) and the WMa, in order to 
expand this debate. It was followed by a meeting of the WMa ethical Committee 
and national representatives of the above mentioned working group. In this 
seminal and exemplary event, those two controversial topics were discussed, but 
no consensus was reached, and the Brazilian representatives positioned themselves 
against the WMa’s proposal.
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table 1 – declaration of Helkinsi: Proposal by the World Medical association (WMa) 
approved in  the 2008 General assembly (seoul, south Korea) and position 
defended by the Brazilian Medical association (aMB) and the Federal Council of 
Medicine (CFM)
Item Proposal approved in 2008 Proposal defended by the AMB and CFM, October 18th 2008
Access to medical care
33
At the conclusion of the study, patients 
entered into the study are entitled to 
be informed about the outcome of the 
study and to share any benefits that 
result from it, for example, access to 
interventions identified as beneficial 
in the study or to other appropriate 
care or benefits. 
All patients entering a study must have 
access to the best methods proven 
prophylactic, diagnostic or therapeutic 
identified in the study. 
Placebo use
32
 The use of placebo, or no treatment, 
is acceptable in studies where no 
current proven intervention exists; or 
where for compelling and scientifically 
sound methodological reasons 
the use of placebo is necessary to 
determine the efficacy or safety of 
an intervention and the patients who 
receive placebo or no treatment will 
not be subject to any risk of serious or 
irreversible harm.
The benefits, risks, onus and 
effectiveness of a new method must 
be tested in comparison to the best 
proven care, except in the following 
circumstance:
- The use of placebo or no treatment 
is acceptable in studies in which no 
efficient method has been proven.
the Brazilian Medical association, the Federal Council of Medicine, 
the national Commission of Research ethics (comissão Nacional de Ética em 
Pesquisa, ConeP) and the Ministry of Health (represented by the department 
of science and technology) were in favor of maintaining the restrictions on the 
use of placebo and guaranteeing volunteer access to what the study proves to be 
effective.
In the General assembly of the World Medical association, held in 
seoul, south Korea, in october 18th 2008, to discuss and approve the new 
declaration of Helsinki, this position was defended, with the firm support from 
the representatives from south africa, Portugal and uruguay, but unfortunately 
it was defeated in the plenary.
Furthermore, Brazil also voted against the approval of the text of the new 
declaration of Helsinki, being consistent with its disagreement on these two items.
thus, the new version of the declaration of Helsinki maintained the texts 
shown in table 1.
as mentioned before, the Brazilian representatives voted against the 
proposals for these two items because they understood that: in relation to the 
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placebo, there is no plausible ethical justification for not using as a comparison 
a medication that has been proven to be effective, and the reasons for the use 
of placebo in these situations are purely economic and/or related to markets; 
on the post-study access: because keeping the phrase “or other care or benefits” 
opens the possibility of not guaranteeing post-study access to interventions 
identified as beneficial. these “other care or benefits” may be interpreted in 
several ways which are harmful to the volunteer, especially in conditions of 
greater vulnerability.
Resource allocation
Confirming a World Bank report, urban poverty has turned into one of 
the most explosive political and economical problems of the 21st century. the 
emergence of megalopolises, cities with more than ten million inhabitants, 
typical of underdeveloped nations, where more than 50% of the population 
does not have access to treated water or a sewage system, is a portrait of these 
problems. In the beginning of this 21st century, 20 out of the 25 largest urban 
centers in the world are located in the poorest regions of the planet.
according to estimates, almost one billion people still suffer from hunger 
today and approximately 25% of the urban population of the third World lives 
in conditions of absolute poverty. the budget dedicated to health is usually 
insufficient: in PPP (parity purchase power) terms, the largest investment was 
made by the united states (12nd place in the Human development Index), us$ 
1.520 by Brazil (70th in the HdI) and about us$ 34 by sierra Leone (last place 
in the HdI: 177th) (WHo, 2007).
Much has been written about to the enormous additional investment 
in healthcare imposed by the aIds epidemic, both in terms of direct costs 
(medications, ambulatory care, hospitalizations) and in terms of indirect 
ones (education, prevention, loss of years of work). even considering all the 
possibilities to reduce these costs through the involvement of all society groups 
(family, friends, nGos, day hospitals), the necessary investments will still be 
much greater than the resources made available. the global investment in aIds 
control raised exponentially (us$ 1 billion in 2001, reaching us$ 8.2 billion 
in 2007), although it is estimated that us$ 20 billion will have been necessary 
in 2008, and the need shall increase in the coming years. this need may be 
illustrated by the fact that, for each new treatment that is instituted, there are 
2.7 people who get infected by HIv. this rise in investments coincided with the 
historical commitment of the united nations to combat the aIds epidemic, 
defined in the General assembly special session on HIv/aIds (unGass). 
one must also highlight the fact that, in most third World countries, the aIds 
impact adds to an existing long list of endemic or emergent diseases (such as 
tuberculosis, leprosy, schistosomiasis, leishmaniasis, malaria).
the idea that funding for health expenses should be prioritized in 
relation to other public expenses has been gaining momentum; for example, 
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funding for health should be raised by decreasing the budget for military 
expenses, which reached us$ 1.2 trillion, half of which spent by the united 
states. unfortunately, the most common scenario is usually one in which 
expenses for aIds control are taken from the total health budget, and any rises 
may mean less money for other diseases. Here, pressure from society to change 
this kind of resource allocation is certainly in order.
the structural adjustments determined by the World Bank and the 
International Monetary Fund (IMF) in the last decades of the 20th century, 
associated with the capital crisis that happened after the fall of the Berlin Wall 
and that in 2008 is represented by the serious north-american and global 
economic crisis, have worsened the social conditions of a substantial part of the 
world’s population, which will certainly further facilitate the worsening of the 
health situation globally. thus, the most efficient application of the available 
resources, the decision on where and how to use them and how to counteract 
the interference of international agencies (World Bank, IMF) on this decision 
are only some of the challenges to be faced.
Lessons
Confronting AIDS in Brazil
In 1986, the Ministry of Health created the Brazilian Program on 
std/aids (Pndst/aids) and put it in charge of establishing a national plan 
to confront the epidemic. table 2 shows some important milestones in the 
establishment of this program and in the access to anti-retroviral treatment. In 
1996, the national Congress promulgated, with the support and pressure from 
organized civil society, a law that made it compulsory to provide universal access 
to anti-retroviral therapy to all that need it, at no additional cost (Portela et. 
al, 2006; teixeira et al., 2004). this decision went into the opposite direction 
from the common sense idea according to which developing countries should 
focus on prevention efforts to confront aIds, because the complexity of the 
therapeutic schemes would make patient adherence to treatment difficult, 
increasing the risk of dissemination of resistant viruses. From 1996 to 2002, the 
Brazilian government’s total investment in this sort of treatment reached us$ 
1,6 billion. along with its enormous social impact, by diminishing mortality, 
morbidity, as well as the number of hospitalizations, medical leaves and early 
retirements (teixeira et al., 2004), almost us$ 2 billion were spared. today, the 
program’s good results are internationally acknowledged (Parker & Camargos 
Jr., 2000) and the rates of resistant virus transmission are lower than those of 
many developed countries. the provision of universal access to anti-retroviral 
drugs (aRv) and to adequate aIds healthcare proved that it is possible for a 
developing country, even one with so many inequities, to treat people equally, 
independently of race, gender or economic power. Here we are talking not about 
the controlled and self-limited situation existent in a clinical trial, in which 
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the cost of providing such care to the volunteers is a fraction of the millions of 
dollars spent not only on the trial itself but also, in significant amounts,  
on marketing.
this approach has been defended (steinbrook, 2006) and has already been 
adopted by many other developing nations, with WHo support. one example is 
the 3 by 5 initiative, which aimed to make anti-retroviral medication available to 
3 million people by 2005, mobilized efforts from all over the world and received 
funding from many sources.
table 2 – Relevant events for aids treatment policy In Brazil
Year Relevant event
1986 Establishment of the National Program on STD/Aids
1988 New Brazilian Constitution (Single Health System, SUS)
1991 AZT distribution begins
1995 Local production of anti-retroviral medication begins
1996 Legislation secures the right to anti-retroviral medication
2001
57º Session of the UN Commission on Human Rights: access to medication 
to treat pandemics is a basic human right; Brazil produces seven out of the 
thirteen medications
2003
Presidential decree makes it easier to import generic medication produced 
under compulsory licensing
2007 Compulsory licensing is issued for the anti-retroviral medication efavirenz
  
Perspectives
despite all the problems and difficulties listed above, it is actually possible 
to fight for the improvement of the current state of poverty and badly-distributed 
wealth, a backdrop for disease dissemination. among the viable mechanisms 
for this is the involvement of professionals and civil society, acting together 
in the Health Councils and participating in budget decisions. these fora can, 
among other things, influence decisions to fund studies that are really relevant 
and ethical, in order to improve basic sanitary conditions and epidemiological 
surveillance, as well as the access to quality healthcare for all.
Internationally respected ethical rules for research
a good example was set by the intense discussions which have taken 
place in the past ten years in relation to proposed changes to the declaration of 
Helsinki: activists, ethicists and scientists have been able to work together to resist 
maneuvers to lower the ethical standards for clinical trials which can increase even 
more the abyss that separates affluent populations from developed countries from 
most of the rest of the world’s population.
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Civil society participation
one of the ways to counterbalance the use of power in decision-
making and funding allocation related to public health policies is through the 
strengthening (emancipation) of people/citizens. one example to be followed 
is that of people living with HIv/aids in the fight for their rights in all 
possible fora, including international conferences, national and international 
aIds organizations and even in regulatory agencies. this made a great deal of 
difference in all aspects of the struggle to control this epidemic – from prevention 
to treatment, from debates about rights to pressure for the development of 
efficient drugs and vaccines. one does not hear much, however, about  effective 
participation of people living with malaria, schistosomiasis, Chagas disease or 
hepatitis in conferences or discussion tables about these diseases. But there 
are millions of people living with one (or more than one) of these diseases in 
developing countries. Here, education may be a sine qua non condition to change 
the situation, taking into account that it was especially from people with access to 
education that the great pressure exerted by civil society emerged in relation to 
the necessary measures to face the HIv/aids epidemic.
Challenges to the sustainability of the Brazilian program to control Aids
there are challenges to the sustainability of the Brazilian program and 
they include:
the weight of success: the very existence of a successful program may 
contribute to a lower degree of involvement – and consequently lower 
political pressure – from civil society, including the media.
By the same token, since the Brazilian program offers the best treatment 
available internationally, there is also the risk that healthcare professionals 
do not worry enough about follow-up and change the treatment too 
early to more complex anti-retroviral schemes. If this happens, the  use of 
alternatives prematurely will raise the costs of the new drugs, which are 
generally more expensive, usually patent protected and have been tested for 
a shorter period of time.
the monopolistic or oligopolistic configuration of the active ingredients 
market: despite the fact that Brazil produces eight anti-retroviral 
medications locally, except for the efavirenz, all active principle ingredients 
(aPI) are imported, generally from asia. this situation is particularly 
serious because of the possible scarcity of aPIs due to the rise in 
consumption of anti-retroviral drugs by public and private programs all 
over the world.
the great challenge of poverty and inequality (Greco, 1992; Phanuphak, 
1998): the relationship between poverty and dissemination of epidemics 
has been proven beyond doubt, and these epidemics have a very high 
potential of increasing poverty. the effect of increased poverty is more 
than financial, because the disease and consequent mortality lead to 
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the erosion of social capital and family unity. Poverty increases the 
vulnerability to infection by HIv, because it makes access to healthcare 
and to the complexity of therapeutic methods more difficult, besides 
preventing the maintenance of necessary prevention.
a last and very important obstacle for long term sustainability is a short-
sighted perception, to which the pharmaceutical industry propaganda 
contributes, that intellectual property rights issues are not relevant. this 
may be an unexpected side-effect of the various programmes to scale up 
treatment (FGatM, PePFaR, Gates etc.), where the opportunity to get 
treatment may blur the long-term debate on the need for local production 
and technical independence and may jeopardize long term sustainability. 
also, some free trade agreements are having an impact in drug prices 
and that affects sustainability on a long-term basis. use of the tRIPs 
flexibilities, including compulsory licensing to buy generics and to produce 
locally is still incipient, although there are now many aRv generic versions 
pre-qualified by WHo.
these challenges must be faced in order to lower the risk of not being able 
to guarantee long-term sustainability of the Brazilian program, because:
there is an expectation that an increasingly high number of people will 
need treatment: according to estimates, there are approximately 600,000 
people living with HIv in Brazil (szwarczwald & Carvalho, 2000), 
180,000 of which have already been diagnosed and are being treated, and 
20,000 new treatments are started annually;
the current investments in anti-retroviral medications is about us$ 400 
million/year, an amount which will certainly increase with the expected 
need for imported and increasingly expensive third line treatments;
the poverty backdrop: even with free access to healthcare, lab tests and 
adequate distribution of medication in this continent-sized country, the 
expansion of the epidemic to poor people in small towns means that they 
do not always have money to buy public transportation tickets to reach 
healthcare centers.
Perspectives to warrant sustainability
the exemplary role played by Brazil and the unquestionable success of its 
aIds program are reasons enough to seek viable mechanisms to warrant its long 
term sustainability. this mechanisms are complex and multifactorial.
 Governance
a) Mechanisms initiated by Brazil and depended only on the country.
Many aspects related to sustainability depend only on Brazilian policies:
there is an urgent need to promote the “rational use” of anti-retroviral 
drugs, including policies to wait until more robust scientific evidence has 
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been collected before including new drugs into the Brazilian treatment 
consensus. although since 1996 Brazil has adopted detailed guidelines 
for aIds treatment, which are revised every year, there is a need for more 
data on the effectiveness of the various schemes for their rational use. 
the strong pressures from the pharmaceutical industry to introduce new 
drugs must be counterbalanced by local operational research, using the 
enviable amount of information collected from the 180,000 people now in 
treatment.
to increase local production, including better formulations of existing 
medication: Investing in public labs (and also in national private ones) to 
increase local production at compatible prices – not only for drugs but 
also to stimulate the production of aPIs. there is also the need for better 
pediatric formulations and also for production of fixed associations, such as 
the one with azt-3tc-nevirapine, which has been available for a long time in 
other countries.
More investments in research, including for developing more molecules 
and aPIs. For example: the establishment of a Brazilian factory in the 
state of acre with an initial production of 100 million condoms per 
year;  the development of tests for  determining viral load and for tCd4 
lymphocytes determination.
b) International collaboration
Lowering the price of anti-retroviral drugs:
even though this is a short term policy, it is a significant component of the 
maintenance of universal access to treatment. In this quest, the amount 
of resources invested annually in the production and purchase of anti-
retroviral drugs is, undoubtedly, an important tool in the negotiation 
table. Brazilian participation in regional initiatives led by the Pan-
american Health organization (PaHo) and international ones, such as 
unitaid (http://www.unitaid.eu), has contributed to expand global access 
to these drugs.
c) Political decision and international participation
despite all the experience accumulated by the Pndst/aids, which has 
been dealing for three decades with all this epidemic’s complex aspects, and 
despite all the financial and political involvement, the growing complexity and 
the higher costs of new drugs protected by patents are a threat to the available 
resources for health. thus, the political decision to implement local production at 
reasonable prices becomes an unquestionable necessity. and the legal instruments 
to issue compulsory licensing are backed by the trips agreement flexibility when 
it comes to protecting public health (Fairchild & Bayer, 1999). In May 2007, 
the Brazilian government decided for the first time to issue compulsory licensing 
for the import and future local production of the generic version of the anti-
retroviral drug efavirenz. this bold decision is obviously not the solution for 
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the Program’s sustainability, but it showed that, in situations where universal 
access to public healthcare is at stake, these exceptional measures are clearly in 
order. With compulsory licensing, each efavirenz pill, which costed us$ 1.55 in 
the patented version, could be acquired for us$ 0.45, saving an estimated us$ 
30 million annually. the fact is that the seriousness, visibility and accumulated 
experience of the Brazilian program make it easier for the country to be more 
vocal and act according to what is best for public health, together with other 
international partners, in the quest for opening the black boxes related to the 
cost of developing and producing these medications, with the aim of establishing 
mechanisms for technology transfer and local production.
these examples reinforce the argument that today there is no longer room 
for asking IF granting clinical trial volunteers access to the best healthcare is an 
ethical requirement or not, as this IF must be replaced by HoW to work together 
to universally provide both the needed products that prove to be efficient and 
decent healthcare for all.
Conclusions
there are many uncertainties about what the future reserves for the aIds 
epidemic, as well as for the infectious and parasitical diseases known today and 
those which we will certainly come to face, and the perspective of attaining health 
for all in the year 2000 has been irremediably postponed. the needed changes are 
many, and most of them are well-known:
access to education, employment, housing; access to healthcare; all 
included in the universal declaration of Human Rights (articles 18, 25.1, 
united nations, 1948).
the need for global involvement has been proclaimed as necessary for 
everyone to have access to health, but unfortunately this motto and 
the cited articles of the universal declaration of Human Rights are 
still rhetorical figures. the number of people who are starving is still 
intolerably high and has been getting even higher, and this growth 
coincides with the expansion of globalization.
In order to control endemics and epidemics, all efforts must be combined 
to: prevent their dissemination, with the continuous education of all 
on preventive methods; disseminate our urgings for solidarity and non-
discrimination;  encourage ethically appropriate research for new drugs, 
diagnostic tests and vaccines.
unfortunately, inequality in health will not be solved by research or 
researchers, but, if people are treated equally in clinical studies, there will be 
equality in those studies, and they can be the first step for broader aims. thus, 
a good start is the certainty that ethical requirements defined by unquestionable 
international guidelines, are applied equally all over the world. the certainty 
that equality shall be respected in clinical research may be an important step 
toward reverting the current injustice in health resources allocation, and may also 
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contribute to strengthen (emancipate) people (volunteers, researchers and civil 
society), enabling them to learn their rights as citizens and to fight for them. If 
it is not possible to reach this equality in such a controlled environment as is the 
one of clinical research, how will we make it happen in the real world?
In reality, without education, resources and healthcare, there is no 
perspective of controlling diseases. and access to these will only happen after 
considerable changes in the international order toward greater justice and 
equality, better income distribution and social protection. Clearly, this new 
international order can only be achieved with changes in each nation; it is truly 
difficult to cry for international justice when disparity in Brazil is so blatant. It is 
necessary - and it is worth repeating it – to exchange the paradigm of monetary 
and market values for one that values the human being. In this way, Brazil shall 
certainly be able to assert itself as a nation, opposing itself to the neoliberal values 
of the current economic order.
Will, however, the concerted action of all sorts of activists and health 
professionals exert enough pressure to improve the allocation of education and 
health resources, to improve wealth distribution? Probably not, but it means 
that our voices of indignation against the status quo will be heard. our role as 
active citizens is to multiply and amplify the cry for justice and equality for all, 
independently from race, religion, origin or language.
Finally, thucydides (465-395 b.C.) said that justice would only be 
achieved when those who are not victims of injustice become as indignant 
as those who are. I dare say that justice will only prevail when those who are 
affected by injustice become aware of their rights and fight for them.
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AbstrAct - the emergence of the aids epidemic and the increase in the incidence 
of HIv infection are still a health challenge for the 21st century. the way the epidemic 
is being confronted and how it will be in the years to come will be of fundamental 
importance on the discussion of public health, ethics and human rights. the diverse 
aspects of the epidemic are here discussed, including the possible interventions necessary 
to its control. Changes in the decision-making process for the allocation of resources, 
both for public health care and research, as well the expansion of the ethical debate and 
the need to improve the standard of living of all individuals, are imperative conditions in 
order to face this very serious public health problem. 
Keywords: epidemic of the aids, ethics, social impact, scientific impact, economic 
impact, Perspectives.
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